AlphaCentric Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
Other funds holding JAZZ
AlphaCentric Advisors's JAZZ Position: Q3 2026 in Review
AlphaCentric Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 30% in Q3 2026, buying an estimated $266K and bringing the position to 4,688 shares worth $1.09M. The position accounts for 0.96% of the portfolio, ranked #18.
AlphaCentric Advisors first reported a position in JAZZ in Q2 2020 and has held it in 16 quarters since. The position peaked at $5.05M in Q2 2023. 671 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.
- AlphaCentric Advisors held 4,688 shares of Jazz Pharmaceuticals worth $1.09M as of Q3 2026.
- AlphaCentric Advisors bought 1,075 Jazz Pharmaceuticals shares in Q3 2026, an estimated $266K.
- Jazz Pharmaceuticals made up 0.96% of AlphaCentric Advisors's portfolio in Q3 2026, its #18 holding.
- AlphaCentric Advisors first reported a position in Jazz Pharmaceuticals in Q2 2020 and has held it in 16 quarters since.
- AlphaCentric Advisors's Jazz Pharmaceuticals position peaked at $5.05M in Q2 2023.
- 671 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.
Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.